Future studies should also evaluate bavachinin’s effects in other thyroid cancer subtypes and investigate potential synergistic effects with existing kinase inhibitors or chemotherapy, especially in aggressive tumors harboring dual pathway activations (e.g., BRAF/PTC or RAS mutations). This evidence concerns the gene BRAF and thyroid gland carcinoma.